Core Viewpoint - He Yu-B (02256.HK) is identified as a leading player in the small molecule innovative drug sector, with projected revenues and net profits showing consistent growth from 2025 to 2027 [1] Financial Projections - Expected revenues for He Yu-B are RMB 650 million, RMB 680 million, and RMB 730 million for the years 2025, 2026, and 2027 respectively [1] - Projected net profits are RMB 97 million, RMB 111 million, and RMB 142 million for the same years [1] - The DCF model indicates a target price of HKD 22.06, representing a potential upside of 48.5% from the current price [1] Analyst Ratings - The majority of investment banks have rated He Yu-B as a "Buy," with 7 firms issuing buy ratings in the last 90 days [1] - The average target price from these ratings is HKD 20.75 [1] - Tianfeng Securities recently issued a buy rating with a target price of HKD 22.88 [1] Market Position - He Yu-B has a market capitalization of HKD 9.985 billion and ranks 17th in the biopharmaceutical II industry [2] - Key financial metrics compared to the industry average show that He Yu-B has a return on equity (ROE) of 7.24%, which is below the industry average of 10.46% [2] - The company has a net profit margin of 53.66%, significantly outperforming the industry average of -381.46% [2] - He Yu-B's gross margin is 100%, the highest in the industry, while its debt ratio stands at 8.93%, well below the industry average of 74.41% [2]
国元国际发布研报称，和誉-B(02256.HK)是小分子创新药龙头